Tag: MRD
A desirable transgenic strategy using GGTA1 endogenous promoter-mediated knock-in for xenotransplantation model
Lai, L. et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295, 1089–1092. doi.org/10.1126/science.1068228 (2002). ADS CAS Article PubMed Google Scholar Kuwaki, K. et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat. Med. 11, 29–31. doi.org/10.1038/nm1171 (2005). CAS Article PubMed Google…
cfDNA-Based NGS IG Analysis in Lymphoma
Circulating cell-free DNA (cfDNA) is fragmented extracellular DNA, which is released from apoptotic and necrotic cells in small fragments of <200 bp [1]. cfDNA is typically isolated from the blood stream; however, it is also possible to detect cfDNA in other biological fluids such as urine or cerebrospinal fluid [2, 3,…
Fortis Life Sciences Inks Distribution Deal for AccuGenomics NGS Standards Tech
NEW YORK — Fortis Life Sciences, a provider of capital and other resources to life science tool companies, said on Tuesday that it has signed a deal to distribute AccuGenomics’ SNAQ-SEQ internal standards technology for next-generation sequencing in the US and Europe. Under the terms of the deal, Waltham, Massachusetts-based…
Anti-CD19 CAR T-Cell Therapy for B-Cell Lymphoma
Researchers reported a favorable efficacy and manageable safety profile in anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with B-cell lymphomas. Their data is presented in Frontiers in Genetics. Researchers, led by Wenyujing Zhou, aimed to determine the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy…
h2o AutoML vs h2o XGBoost – model metrics
The problem here is that you are comparing training metrics for XGBoost to CV metrics for AutoML models. The code you posted for the manual XGBoost models provides training metrics. Instead, you will need to grab the CV metrics if you want to make a fair comparison to the performance…
MRD Surveillance in DLBCL – Capsule Summary Slidesets – Lymphomas and CLL – 2021 ASH Annual Meeting – Oncology
December 11-14, 2021; Atlanta, Georgia Results of this study showed that substantial proportions of clinical relapses were radiographically detected in asymptomatic patients, whereas immunosequencing MRD monitoring demonstrated suboptimal sensitivity. Format: Microsoft PowerPoint (.ppt) File Size: 484 KB Released: December 16, 2021 …
Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients
“Our longstanding relationship with the NSABP, through our work to develop and validate the Oncotype DX Breast Recurrence Score® and Colon Recurrence Score® tests, represents a remarkable collaboration between academic and industry partners. This relationship has fueled major advancements in understanding the role of molecular profiling in breast and colon…
Novel Test Distinguishes Benign From Malignant Lesions in NF1
A novel liquid biopsy test has been shown to distinguish between patients with neurofibromatosis type 1 (NF1) who have benign plexiform neurofibroma (PN) precursor lesions from patients who have malignant peripheral nerve sheath tumors (MPNST), say authors of a multi-institutional cross-sectional study. “Transformation from PN to MPNST is challenging to…
Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology
Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…
Dissecting Cancer with Single-cell DNA Sequencing & Multi-omics | Learning Center
CANCER & SINGLE-CELL ANALYSIS The heterogeneity and dynamism of cancer present formidable challenges to understanding and treating the disease. As discussed in the last section, tumor evolution often leads to considerable genetic variation across clones. But the complexity of tumors does not stop at the level of DNA. Intratumoral phenotypic…